Clinical Trials

We partner with researchers from around the world to conduct clinical trials studying our investigational therapies.

Retrophin is committed to research and development of new therapies for rare disease. We are involved in numerous clinical trials for our pipeline product candidates targeting rare conditions. Find links to our clinical trial websites and postings on clinicaltrials.gov below.

We are currently enrolling patients in the following clinical studies:

DUPLEX Study
Product: Sparsentan | Therapeutic area: FSGS
Study type: Phase 3
Learn more: fsgsduplex.com | NCT03493685

PROTECT Study
Product: Sparsentan | Therapeutic area: IgAN
Study type: Phase 3
Learn more: iganprotect.com | NCT03762850

CTX Prevalence Study
Therapeutic area: CTX among patients with early-onset idiopathic bilateral cataracts
Study type: Observational
Learn more: cataractsstudy.com | NCT02638220

CNSA-001 for PKU in collaboration with Censa Pharmaceuticals
Product: CNSA-001 | Therapeutic area: PKU
Study type: Phase 2

REPLACE Registry
Product: Cholic acid | Therapeutic area: BASD or ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086

Active clinical studies with completed enrollment:

DUET Study
Product: Sparsentan | Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118

FORT Study
Product: Fosmetpantotenate | Therapeutic area: PKAN
Study type: Phase 3
Learn more: NCT03041116

To learn more about our clinical trials, including enrollment and study centers, contact Retrophin at medinfo@retrophin.com or visit Clinical Trials.gov.